Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 26141-26150 Newer>

The Motley Fool September 18, 2007 Rich Duprey	Beazer's House of Cards The homebuilder teeters on the edge of bankruptcy as bondholders circle like vultures awaiting its default. Investors take note.
The Motley Fool September 18, 2007 Tim Hanson	The Best Thing to Happen to Stocks This Year The Fed decides to cut the federal funds rate 50 basis points, all the way down to 4.75%. The entire market jumped on the news. Investors, what does the cut really mean for your stocks?
The Motley Fool September 18, 2007 Lawrence A. Rothman	AutoZone Needs to Refuel Its Sales The auto-parts company revved up its earnings per share again this quarter, but sales are still stalled.
The Motley Fool September 18, 2007 Bill Mann	Say Good Night, LENDie This subprime lender's days seem numbered. Buying LEND shares at $10, counting on a $15 deal when the company says it's on life support, seems like the worst kind of faith-based initiative. It's like a game of chicken.
The Motley Fool September 18, 2007 Brian Orelli	PDUFA Reauthorization: Almost There Much to the applause of drug makers and those who invest in them, the Prescription Drug User Fee Act reauthorization looks like it could come out of a Congressional conference committee as early as this week.
The Motley Fool September 18, 2007 Timothy M. Otte	Refinance Your Vegetables? Kroger gradually expands its financial services. But smart investors should focus on the grocer's strong traffic and comparable-store sales growth in recent quarters.
The Motley Fool September 18, 2007 Toby Shute	Ethanol Is Not the Answer If you're looking beyond petroleum, you're overlooking some of today's smartest energy investments.
The Motley Fool September 18, 2007 Brian Orelli	Another Partnership for Personalized Medicine Celera gets a contract to design a companion diagnostic test for Merck. Investors, take note.
The Motley Fool September 18, 2007 Brian Lawler	Direct Your Attention to DURECT Promising drug test results make DURECT a company to watch. The tiny drugmaker has a host of important milestones coming up over the next year.
The Motley Fool September 18, 2007 Tom Taulli	Icahn Beats Up BEA Why has the legendary corporate activist set his sights on the struggling software developer? Investors, take note.
<Older 26141-26150 Newer> Return to current articles.